SynthesisBJU international2019
A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens.
Synthesis in BJU international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Oncologic outcomes of transurethral resection versus laser excision for non-muscle invasive bladder cancer: a SEER retrospective cohort study.Translational andrology and urology · 2026Article
- Clinical outcome of BCG treatment for patients with urothelial carcinoma of the prostatic urethra: Implications for early cystectomy.World journal of urology · 2025Article
- Validation of clinical T stages and of prognostic negative markers in patients with muscle invasive bladder cancer: data in the Swedish National Bladder Cancer RegistryTranslational andrology and urology · 2024Article
- Predicting the Lymphovascular Invasion in Carcinoma Bladder at Transurethral Resection.Cureus · 2024Article
- Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder Cancer.JCO precision oncology · 2024Article
- Artificial Intelligence can Facilitate Application of Risk Stratification Algorithms to Bladder Cancer Patient Case Scenarios.Clinical Medicine Insights. Oncology · 2024Article
- Metabolomic Signatures of Treatment Response in Bladder Cancer.International journal of molecular sciences · 2023Review
- Development and validation of a preoperative nomogram to predict lymph node metastasis in patients with bladder urothelial carcinoma.Journal of cancer research and clinical oncology · 2023Article
- Association of patients' sex with treatment outcomes after intravesical bacillus Calmette-Guérin immunotherapy for T1G3/HG bladder cancer.World journal of urology · 2021Article
- Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer.World journal of urology · 2021Article
- Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Full-text.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2021Article
- Impact of Lymphovascular Invasion on Prognosis in the Patients with Bladder Cancer-Comparison of Transurethral Resection and Radical Cystectomy.Diagnostics (Basel, Switzerland) · 2021Article
- Identification of a five-gene signature in association with overall survival for hepatocellular carcinoma.PeerJ · 2021Article
- Review
- Preoperative Clinical Predictors of Lymphovascular Invasion of Bladder Tumors at Transurethral Resection Pathology.Current urology · 2020Article
- Oncological impact of inflammatory biomarkers in elderly patients treated with radical cystectomy for urothelial bladder cancer.Arab journal of urology · 2020Article
- Fibronectin urothelial gene expression as a new reliable biomarker for early detection of local toxicity secondary to adjuvant intravesical therapy for non-muscle invasive bladder cancer.Therapeutic advances in urologyArticle
- Impact of lymphovascular invasion and histological variants on BCG-treated high-grade NMIBC prognosis.Bladder cancer (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present review was to assess the prognostic impact of lymphovascular invasion (LVI) in transurethral resection (TUR) of bladder cancer (BCa) specimens on clinical outcomes. A systematic review and meta-analysis of the available literature from the past 10 years was performed using MEDLINE, EMBASE and Cochrane library in August 2017. The protocol for this systematic review was registered on PROSPERO (Central Registration Depository: CRD42018084876) and is available in full on the University of York website. Overall, 33 studies (including 6194 patients) evaluating the presence of LVI at TUR were retrieved. LVI was detected in 17.3% of TUR specimens. In 19 studies, including 2941 patients with ≤cT1 stage only, LVI was detected in 15% of specimens. In patients with ≤cT1 stage, LVI at TUR of the bladder tumour (TURBT) was a significant prognostic factor for disease recurrence (pooled hazard ratio [HR] 1.97, 95% CI: 1.47-2.62) and progression (pooled HR 2.95, 95% CI: 2.11-4.13), without heterogeneity (I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.